Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical investigation is a prospective, multicenter, single arm clinical evaluation utilizing the multi-electrode radiofrequency balloon catheter and the multi-electrode circular diagnostic catheter.
The objective of this clinical investigation is to assess the safety and acute effectiveness of the multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter when used for the isolation of the pulmonary veins in the treatment of Paroxysmal Atrial Fibrillation (PAF).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radiofrequency Ablation | Device | RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Early Onset Primary Adverse Events (PAEs): Death, Atrio-esophageal Fistula and Pulmonary Vein Stenosis | A Primary AEs is an event which occurred within 90 days following initial ablation procedure. Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis. | Up to 90 days (post initial mapping and ablation procedure) |
| Number of Participants With Early Onset PAEs: Myocardial Infraction, Cardiac Tamponade/Perforation, Thromboembolism, Stroke/Cerebrovascular Accident, Transient Ischemic Attack, Phrenic Nerve Paralysis, and Major Vascular Access Complication/Bleeding | A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure. | Up to 7 days (post initial mapping and ablation procedure) |
| Percentage of Participants With Acute Procedural Success | Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter). | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Individual PAE From Primary Composite | A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included death, atrio-esophageal fistula (AE fistula) and pulmonary vein stenosis (PVST); and up to 90 days post procedure which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
Previous surgical or catheter ablation for AF.
Anticipated to receive ablation outside the PV ostia and Cavo-triscuspid-isthmus (CTI) region
Previously diagnosed with persistent, longstanding AF and/or continuous AF > 7 days, or > 48 hrs terminated by cardioversion.
Any percutaneous coronary intervention (PCI) within the past 2 months.
Valve repair or replacement and presence of a prosthetic valve.
Any carotid stenting or endarterectomy.
Coronary artery bypass grafting (CABG), cardiac surgery (e.g. ventriculotomy, atriotomy), or valvular cardiac surgical or percutaneous procedure within the past 6 months.
Documented left atrium (LA) thrombus on baseline/pre-procedure imaging.
LA antero posterior diameter > 50 mm
Any PV with a diameter ≥ 26 mm
Left Ventricular Ejection Fraction (LVEF) < 40%.
Contraindication to anticoagulation (e.g. heparin).
History of blood clotting or bleeding abnormalities.
Myocardial infarction within the past 2 months.
Documented thromboembolic event [including transient ischemic attack(TIA)] within the past 12 months.
Rheumatic Heart Disease.
Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
Unstable angina.
Acute illness or active systemic infection or sepsis.
Diagnosed atrial myxoma or interatrial baffle or patch.
Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).
Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study.
Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
Enrollment in an investigational study evaluating another device, biologic, or drug.
Has known pulmonary vein stenosis.
Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter.
Presence of an Inferior Vena Cava (IVC) filter
Presence of a condition that precludes vascular access.
Life expectancy or other disease processes likely to limit survival to less than 12 months.
Presenting contra-indication for the devices (e.g. transthoracic echocardiography (TTE), CT, etc.) used in the study, as indicated in the respective instructions for use.
Categorized as a vulnerable population and requires special treatment with respect to safeguards of well-being
Additional exclusion criteria for Neurological Assessment Evaluable (NAE) subjects:
Contraindication to use of contrast agents for MRI such as advanced renal disease, etc. (at PI discretion)
Presence of iron-containing metal fragments in the body
Unresolved pre-existing neurological deficit.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Na Homolce Hospital | Prague | Czechia | ||||
| Ospedale "F. Miulli" |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33450010 | Derived | Schilling R, Dhillon GS, Tondo C, Riva S, Grimaldi M, Quadrini F, Neuzil P, Chierchia GB, de Asmundis C, Abdelaal A, Vanderlinden L, Tan T, Ding WY, Gupta D, Reddy VY. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE. Europace. 2021 Jun 7;23(6):851-860. doi: 10.1093/europace/euaa382. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Roll-in Study Phase: RF Ablation | Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve. |
| FG001 | Main Study Phase: RF Ablation | RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system). |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety Population included all enrolled participants who have undergone insertion of the study catheter.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Roll-in Study Phase: Radiofrequency (RF) Ablation | Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve. |
| BG001 | Main Study Phase: RF Ablation |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Early Onset Primary Adverse Events (PAEs): Death, Atrio-esophageal Fistula and Pulmonary Vein Stenosis | A Primary AEs is an event which occurred within 90 days following initial ablation procedure. Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis. | The population analysis included the modified intent-to-treat (mITT) analysis set included all enrolled participants who met eligibility criteria, had undergone insertion of the study catheters and were followed-up for 90-days period for evaluation of PAEs. | Posted | Count of Participants | Participants | Up to 90 days (post initial mapping and ablation procedure) |
|
Up to 405 Days
The safety population included all participants who have undergone insertion of the study catheter.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Roll-in Study Phase: RF Ablation | Roll-in study phase was to demonstrate the acute effectiveness of the multi-electrode RF balloon catheter in the absence of confounding evidence that reflects early stages of a medical device learning curve. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Major Vascular Access Complication/ Bleeding | Cardiac disorders | MedDRA Version 20.0 | Non-systematic Assessment |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Franchise Medical Director | Biosense Webster, Inc. | 844-434-4210 | ClinicalTrialDisclosure@its.jnj.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 20, 2018 | Jan 29, 2020 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 2, 2018 | Jan 29, 2020 | SAP_001.pdf |
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078703 | Radiofrequency Ablation |
| ID | Term |
|---|---|
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
| D055011 | Ablation Techniques |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 7 days for MI, CT/perforation, thromboembolism, stroke/CVA, TIA, PNP and MVAC (initial mapping and ablation procedure) and up to 90 days for death, AE fistula, and PVST (post procedure) |
| Number of Participants With Serious Adverse Device Effects (SADEs) | An adverse device effect is an adverse event related to the to the device and or the procedure of the investigational medical device. SADE is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. | Up to 405 Days |
| Number of Participants With Serious Non-primary Adverse Events Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and Greater Than or Equal to (>=) 31 Days (Late Onset) of Initial Ablation Procedure | Serious non-primary adverse event was defined as SAE that are not primary adverse events. Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis. | Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days) |
| Number of Participants With Non-serious Adverse Events | An AE is any untoward medical occurrence in participants whether or not related to the investigational medical device. | Up to 405 Days |
| Number of Participants With Pre-and Post-ablation Asymptomatic and Symptomatic Cerebral Emboli | Number of participants with pre-and post-ablation asymptomatic and symptomatic cerebral emboli was reported. | Pre-procedure, at Discharge, 1 Month and at unscheduled visit (Up to 405 Days) |
| Number of Participants With Symptomatic and Asymptomatic Cerebral Emboli | Number of participants with symptomatic and asymptomatic cerebral emboli was reported | Up to 405 Days |
| Number of Participants With New or Worsening Neurologic Deficits | Number of participants with new or worsening neurologic deficits was reported. | Pre-procedure, discharge, 1 Month, 3 Month and 6 Month |
| Number of Participants With NIHSS Scores | The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed to calculate a patient's total NIHSS score. The patient's total NIHSS score ranges from 0 (minimum) - 42 (maximum). Score 0 (no stroke symptoms); 1 - 4 (Minor stroke); 5-15 (Moderate stroke); 16-20 (Moderate to severe stroke); and 21-42 (Severe stroke). | Pre-procedure and at discharge (Up to 405 Days) |
| Number of Participants With MoCA Scores | Montreal Cognitive Assessment (MoCA) is used for detecting cognitive impairment, the scores range from 0 to 30. A score of 26 or higher is considered normal, patients with mild cognitive impairment (MCI) were scored an average of 22 and patients with significant cognitive impairment (SCI) were scored an average of 16. | Up to 405 Days |
| Number of Participants With Hospitalization for Cardiovascular Events | Hospitalization was defined as prolonged stay greater than or equal to (>=) 2 nights post index procedure or in-patient stay not concurrent with index procedure >= 1 calendar day. Hospitalization included cardiovascular events due to any cause post index procedure, regardless of protocol-defined serious/non-serious adverse events (AEs) or not. Hence this data was not contributed in serious Adverse events until met the AE definition. | Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days) |
| Percentage of Participants With PVI Touch-up by Balloon and/or Focal Catheter Among All Targeted Veins and by Participants | Percentage of participants with PVI touch-up by balloon and/or focal catheter among all targeted veins and by participants was reported. Most of the participants were ablated by Balloon catheter only while one participant was ablated with both Balloon and Focal catheters. | Up to 405 Days |
| Percentage of Participants With Use of Focal Catheter Ablation for Non-PV Triggers | Percentage of participants with use of focal catheter ablation for non-PV triggers was reported. | Up to 405 Days |
| Percentage of Participants With Freedom From Documented Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atypical (Left Side) Atrial Flutter (AFL) Episodes or Documented Symptomatic AF/AT/AFL | Percentage of participants with six-month arrythmia recurrence [defined as freedom from documented symptomatic or asymptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atypical (left side) atrial flutter (AFL) episodes (episodes >30 seconds on arrhythmia monitoring device from Day 91 to 180 post the index procedure)] was reported. | Up to 6 Months |
| Percentage of Participants With Freedom From Documented, AF, AT, or Atypical (Left Side) AFL Episodes or Documented Symptomatic AF/AT/AFL | Twelve-month Arrythmia recurrence is defined as a documented symptomatic or asymptomatic episode >30 seconds on an arrhythmia monitoring device between day 91 to 365 post the index procedure. | Up to 12 Months |
| Bari |
| Italy |
| Centro Cardiologico Monzino | Milan | Italy |
| Liverpool Heart and Chest Hospital | Liverpool | United Kingdom |
| Bart's Health NHS Trust | London | United Kingdom |
RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system). |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
|
|
| Primary | Number of Participants With Early Onset PAEs: Myocardial Infraction, Cardiac Tamponade/Perforation, Thromboembolism, Stroke/Cerebrovascular Accident, Transient Ischemic Attack, Phrenic Nerve Paralysis, and Major Vascular Access Complication/Bleeding | A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure. | The population analysis included the modified intent-to-treat (mITT) analysis set included all enrolled participants who met eligibility criteria, had undergone insertion of the study catheters and were followed-up for 90-days period for evaluation of PAEs. | Posted | Count of Participants | Participants | Up to 7 days (post initial mapping and ablation procedure) |
|
|
|
| Primary | Percentage of Participants With Acute Procedural Success | Acute procedural success is defined as confirmation of entrance block in treated pulmonary veins (PV) after adenosine and/or isoproterenol challenge (with or without the use of a focal catheter). | PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. Population included participants who had the adenosine/isoproterenol challenge. | Posted | Number | Percentage of participants | Day 1 |
|
|
|
| Secondary | Number of Participants With Individual PAE From Primary Composite | A Primary AEs is an event which occurred within the first week (7 days of the initial mapping and ablation procedure) which included death, atrio-esophageal fistula (AE fistula) and pulmonary vein stenosis (PVST); and up to 90 days post procedure which included myocardial infraction (MI), cardiac tamponade (CT)/perforation, thromboembolism, stroke/cerebrovascular accident (CVA), Transient ischemic attack (TIA), phrenic nerve paralysis (PNP), and major vascular access complication (MVAC)/bleeding following initial ablation procedure. | The population analysis included the mITT analysis set included all enrolled participants who met eligibility criteria, had undergone insertion of the study catheters and were followed-up for 90-days period for evaluation of PAEs. Here 'N' (number of participants analyzed) signifies the number of participants analyzed in this outcome measure. | Posted | Count of Participants | Participants | Up to 7 days for MI, CT/perforation, thromboembolism, stroke/CVA, TIA, PNP and MVAC (initial mapping and ablation procedure) and up to 90 days for death, AE fistula, and PVST (post procedure) |
|
|
|
| Secondary | Number of Participants With Serious Adverse Device Effects (SADEs) | An adverse device effect is an adverse event related to the to the device and or the procedure of the investigational medical device. SADE is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. | The safety population was defined to consist of all enrolled participants who have undergone insertion of the study catheter. | Posted | Count of Participants | Participants | Up to 405 Days |
|
|
|
| Secondary | Number of Participants With Serious Non-primary Adverse Events Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and Greater Than or Equal to (>=) 31 Days (Late Onset) of Initial Ablation Procedure | Serious non-primary adverse event was defined as SAE that are not primary adverse events. Primary AEs included: Death, atrio-esophageal fistula, and pulmonary vein stenosis. | The safety population was defined to consist of all enrolled participants who have undergone insertion of the study catheter. Here 'n' (number analyzed) signifies the number of participants analyzed at specified timepoints. | Posted | Count of Participants | Participants | Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days) |
|
|
|
| Secondary | Number of Participants With Non-serious Adverse Events | An AE is any untoward medical occurrence in participants whether or not related to the investigational medical device. | The safety population was defined to consist of all enrolled participants who have undergone insertion of the study catheter. | Posted | Count of Participants | Participants | Up to 405 Days |
|
|
|
| Secondary | Number of Participants With Pre-and Post-ablation Asymptomatic and Symptomatic Cerebral Emboli | Number of participants with pre-and post-ablation asymptomatic and symptomatic cerebral emboli was reported. | Neurological Assessment Evaluable (NAE) Analysis set was a subset of the Per Protocol Population, consented and were eligible for the required neurological assessments, and had post-ablation MRI. Here 'n' (number analyzed) signifies participants with MRI done at specified time point. | Posted | Count of Participants | Participants | Pre-procedure, at Discharge, 1 Month and at unscheduled visit (Up to 405 Days) |
|
|
|
| Secondary | Number of Participants With Symptomatic and Asymptomatic Cerebral Emboli | Number of participants with symptomatic and asymptomatic cerebral emboli was reported | The safety population was defined to consist of all enrolled participants who have undergone insertion of the study catheter. | Posted | Count of Participants | Participants | Up to 405 Days |
|
|
|
| Secondary | Number of Participants With New or Worsening Neurologic Deficits | Number of participants with new or worsening neurologic deficits was reported. | Neurological Assessment Evaluable (NAE) Analysis set was a subset of the Per Protocol Population, consented and were eligible for the required neurological assessments, and have post-ablation MRI. Here 'n' (number analyzed) signifies participants with neurological deficit at specified time point. | Posted | Count of Participants | Participants | Pre-procedure, discharge, 1 Month, 3 Month and 6 Month |
|
|
|
| Secondary | Number of Participants With NIHSS Scores | The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed to calculate a patient's total NIHSS score. The patient's total NIHSS score ranges from 0 (minimum) - 42 (maximum). Score 0 (no stroke symptoms); 1 - 4 (Minor stroke); 5-15 (Moderate stroke); 16-20 (Moderate to severe stroke); and 21-42 (Severe stroke). | NAE Analysis set was a subset of the Per Protocol Population, consent and are eligible for the required neurological assessments, and have post-ablation MRI. | Posted | Count of Participants | Participants | Pre-procedure and at discharge (Up to 405 Days) |
|
|
|
| Secondary | Number of Participants With MoCA Scores | Montreal Cognitive Assessment (MoCA) is used for detecting cognitive impairment, the scores range from 0 to 30. A score of 26 or higher is considered normal, patients with mild cognitive impairment (MCI) were scored an average of 22 and patients with significant cognitive impairment (SCI) were scored an average of 16. | NAE Analysis set was a subset of the Per Protocol Population, consent and are eligible for the required neurological assessments, and have post-ablation MRI. Here 'n' (number analyzed) signifies participants analyzed at specified time point. | Posted | Count of Participants | Participants | Up to 405 Days |
|
|
|
| Secondary | Number of Participants With Hospitalization for Cardiovascular Events | Hospitalization was defined as prolonged stay greater than or equal to (>=) 2 nights post index procedure or in-patient stay not concurrent with index procedure >= 1 calendar day. Hospitalization included cardiovascular events due to any cause post index procedure, regardless of protocol-defined serious/non-serious adverse events (AEs) or not. Hence this data was not contributed in serious Adverse events until met the AE definition. | The safety population was defined to consist of all enrolled participants who have undergone insertion of the study catheter. Here 'n' (number analyzed) signifies the number of participants analyzed at specified timepoints. | Posted | Count of Participants | Participants | Within 7 Days (Early Onset), 8-30 Days (Peri-procedural) and >=31 Days (Late Onset) of Initial Ablation Procedure (Up to 405 Days) |
|
|
|
| Secondary | Percentage of Participants With PVI Touch-up by Balloon and/or Focal Catheter Among All Targeted Veins and by Participants | Percentage of participants with PVI touch-up by balloon and/or focal catheter among all targeted veins and by participants was reported. Most of the participants were ablated by Balloon catheter only while one participant was ablated with both Balloon and Focal catheters. | PP analysis set included participants who were enrolled and met all eligibility criteria; had undergone RF ablation with study catheters; and were treated for the study-related arrhythmia. Here 'n' (number analyzed) signifies number of pulmonary veins (PV) in all evaluable participants analyzed at specified category. | Posted | Number | Percentage of participants | Up to 405 Days | PV Veins | PV Veins |
|
|
|
| Secondary | Percentage of Participants With Use of Focal Catheter Ablation for Non-PV Triggers | Percentage of participants with use of focal catheter ablation for non-PV triggers was reported. | PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. | Posted | Number | Percentage of participants | Up to 405 Days |
|
|
|
| Secondary | Percentage of Participants With Freedom From Documented Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atypical (Left Side) Atrial Flutter (AFL) Episodes or Documented Symptomatic AF/AT/AFL | Percentage of participants with six-month arrythmia recurrence [defined as freedom from documented symptomatic or asymptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atypical (left side) atrial flutter (AFL) episodes (episodes >30 seconds on arrhythmia monitoring device from Day 91 to 180 post the index procedure)] was reported. | PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. Here 'N' (number of participants analyzed) signifies the number of participants analyzed in this outcome measure. | Posted | Number | Percentage of participants | Up to 6 Months |
|
|
|
| Secondary | Percentage of Participants With Freedom From Documented, AF, AT, or Atypical (Left Side) AFL Episodes or Documented Symptomatic AF/AT/AFL | Twelve-month Arrythmia recurrence is defined as a documented symptomatic or asymptomatic episode >30 seconds on an arrhythmia monitoring device between day 91 to 365 post the index procedure. | PP analysis set included participants who comply with the following criteria: a). were enrolled and met all eligibility criteria; b). had undergone RF ablation with study catheters; c) were treated for the study-related arrhythmia. Here 'N' (number of participants analyzed) signifies the number of participants analyzed in this outcome measure. | Posted | Number | Percentage of participants | Up to 12 Months |
|
|
|
| 0 |
| 8 |
| 1 |
| 8 |
| 0 |
| 8 |
| EG001 | Main Study Phase: RF Ablation | RF ablation was done using multi-electrode radiofrequency balloon catheter device (facilitate electrophysiological mapping of the heart and to transmit RF current to the target tissue) and multi-electrode circular diagnostic catheter device (recording and mapping of the atria of the heart with the carto system). | 0 | 87 | 2 | 87 | 0 | 87 |
| ST-elevation myocardial infarction | Cardiac disorders | MedDRA Version 20.0 | Non-systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA Version 20.0 | Non-systematic Assessment |
|
| Lumbar vertebral fracture | Injury, poisoning and procedural complications | MedDRA Version 20.0 | Non-systematic Assessment |
|
| Sternal fracture | Injury, poisoning and procedural complications | MedDRA Version 20.0 | Non-systematic Assessment |
|
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| Title | Measurements |
|---|---|
|
| Cardiac tamponade/perforation |
|
| Thromboembolism |
|
| Stroke/cerebrovascular accident (CVA) |
|
| Transient ischemic attack |
|
| Phrenic nerve paralysis |
|
| Pulmonary vein stenosis |
|
| Major vascular access complication/bleeding |
|
| Title | Measurements |
|---|---|
|
|
| 1 Month |
|
|
| Unscheduled visit |
|
|
|
| 1 Month |
|
|
| 3 Month |
|
|
| 6 Month |
|
|
| Title | Measurements |
|---|---|
|
| Pre-procedure: NIHSS Score: 16-20 |
|
| Pre-procedure: NIHSS Score: 21-42 |
|
| Discharge: NIHSS Score: 0 |
|
| Discharge: NIHSS Score: 1-4 |
|
| Discharge: NIHSS Score: 5-15 |
|
| Discharge: NIHSS Score: 16-20 |
|
| Discharge: NIHSS Score: 21-42 |
|
|
| 1 Month: 0-25 |
|
|
| 1 Month: 26-30 |
|
|
| 3 Month: 0-25 |
|
|
| 3 Month: 26-30 |
|
|
| 6 Month: 0-25 |
|
|
| 6 Month: 26-30 |
|
|
| Title | Measurements |
|---|---|
|
| Balloon Catheter Ablation: Left Inferior Pulmonary Vein (LIPV) |
|
|
| Balloon Catheter Ablation: Right Superior Pulmonary Vein (RSPV) |
|
|
| Balloon Catheter Ablation: Right Inferior Pulmonary Vein (RIPV) |
|
|
| Balloon Catheter Ablation: Right Middle Pulmonary Vein (RMPV) |
|
|
| Balloon Catheter Ablation: Left Pulmonary Vein (LPV)-common |
|
|
| Balloon and Focal Catheter Ablation: LSPV |
|
|
| Balloon and Focal Catheter Ablation: LIPV |
|
|
| Balloon and Focal Catheter Ablation: RSPV |
|
|
| Balloon and Focal Catheter Ablation: RIPV |
|
|
| Balloon and Focal Catheter Ablation: RMPV |
|
|
| Balloon and Focal Catheter Ablation: LPV-common |
|
|